Radiopharm Theranostics announced it has extended its agreement with global oncology provider GenesisCare, who will support a second Radiopharm clinical trial in Australia. The trial will use Radiopharm's PSA targeting antibody to start a therapeutic Phase 1 in prostate cancer, with an expected commencement in the coming months. The innovative approach and novel mode of action compared with other treatments currently under development make Radiopharm's technology highly prospective.